-- Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why [Stocks Lose Ground Amid Tariff Uncertainty][Trump's 'Plan B' on Tariffs: More Tariffs][Economy Grew Far Less Than Expected in Q4][Inflation Likely to Keep Fed from Cutting Rates Soon]- Top StoriesWith Monday's drop, Novo Nordisk shares have lost more than half their value in the last 12 months.Kristian Tuxen Ladegaard Berg / NurPhoto / Getty ImagesClose### Key Takeaways- Novo Nordisk's CagriSema, its next-generation weig ...

Novo Nordisk (NYSE: NVO) is taking it on the chin this morning, after revealing the latest clinical trial results for weight loss using its CagriSema drug (a 50-50 mix of amylin analog cagrilintide and Novo's glucagon-like peptide-1 (GLP-1) receptor agonist). After an 84-week trial, Novo reported that its patients achieved 23% weight loss with the drug. That sounds like pretty good news, but investors don't seem to like the number -- and as of 10:10 a.m. ET, Novo Nordisk stock is down 14.8%. Where to inve ...

Group 1 - Novo Nordisk A/S stock has decreased by 14.9% to $40.38 after a trial indicated that its weight loss drug CagriSema was less effective than Eli Lilly's tirzepatide [1] - The stock reached a four-year low of $39.97 and is on track for a fifth consecutive loss, marking its largest single-day percentage drop since July [1] - Over the past year, Novo Nordisk shares have declined by more than 54% [1] Group 2 - Options traders are showing a bullish sentiment, as indicated by a 50-day call/put volume ratio of 4.26, which is higher than 92% of readings from the past year [2] - Today's options activity includes 72,000 calls and 57,000 puts, which is five times the typical volume for this time [3] - The most popular options contracts are the weekly 3/6 40-strike put and May 35 call, with new positions being opened [3] Group 3 - Novo Nordisk has outperformed traders' volatility expectations over the past year, reflected in a Schaeffer's Volatility Scorecard (SVS) of 80 out of 100 [4] - The Schaeffer's Volatility Index (SVI) for Novo Nordisk is in the 23rd percentile of annual readings, suggesting that options are currently affordable [4]

美国贸易政策前景不明令市场情绪承压，美股三大指数集体低开，纳指跌0.03%，道指跌0.31%，标普 500指数跌0.03%。科技股普跌，特斯拉、甲骨文跌超1%。诺和诺德大跌15%，该公司新一代减肥药 CagriSema的试验效果不及礼来的Zepbound。 ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Novo Nordisk A/S ("Novo Nordisk†or "the Company†) (NYSE: NVO) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Novo Nordisk is the subject of a report by CNBC published on February 23, 2026, titled: "N ...

Market Overview - US stock markets opened lower due to uncertainty in trade policies, with the Nasdaq down 0.23%, Dow Jones down 0.05%, and S&P 500 down 0.02% [1] - Major tech stocks experienced declines, with Tesla dropping over 2%, Amazon and Microsoft nearly 2%, and Facebook close to 1% [2] Company Performance - Novo Nordisk's stock fell nearly 14% after its next-generation weight loss drug CagriSema showed a weight loss effect of 20.2% over 84 weeks, compared to Eli Lilly's Tirzepatide, which achieved 23.6% [2][3] - Chinese concept stocks mostly rose, with Atour, NIO, and Hesai Technology increasing over 3%, while Li Auto and Weibo rose over 2% [4] Commodity Market - Gold prices surged, with spot gold nearing $5,200 per ounce, and NYMEX gold rising 2.67% to surpass this threshold [5] - Silver also saw significant gains, with spot silver increasing over 3% [6] - Both Brent and WTI crude oil prices rose by over 0.6% [7] Economic Indicators - The US January CPI rose 2.4% year-on-year, below the expected 2.5%, and core CPI increased by 2.5%, aligning with expectations [8] - The Federal Reserve's January meeting minutes revealed significant internal divisions among committee members regarding inflation persistence [8] - Recent changes in US trade policy include a Supreme Court ruling against large-scale tariffs, followed by an announcement of a 10% import tariff on global goods, which was later increased to 15% [8][9]

诺和诺德(NVO.US)盘初大跌近16%，报39.97美元；礼来(LLY.US)盘初涨超4%，报1055.47美元。诺和诺 德称其减肥药物卡格列肽(Cagrisema)的实验效果不及礼来的替尔泊肽(Zepbound)。 ...

As you know, Novo Nordisk ( NVO ) has just released top-line results from its REDEFINE 4 Phase 3 obesity trial. Overall, the results are clearly a disappointment relative toI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciation for the rigor and challenges behind drug devel ...

Group 1 - The U.S. trade policy outlook remains uncertain, leading to negative market sentiment and a collective decline in major U.S. stock indices [1] - The Nasdaq Composite fell by 0.03%, the Dow Jones Industrial Average decreased by 0.31%, and the S&P 500 index dropped by 0.03% [1] - Technology stocks experienced widespread declines, with Tesla and Oracle both falling over 1% [1] Group 2 - Novo Nordisk's stock plummeted by 15% due to disappointing trial results for its new weight loss drug CagriSema, which underperformed compared to Eli Lilly's Zepbound [1]

联合航空跌1.7%、美国航空跌1.1%、达美航空跌1.5%，受特大暴风雪影响，航空公司被迫在全美范围 内取消航班。Arcellx涨78.1%，吉利德科学将以每股115美元的价格收购Arcellx。诺和诺德跌15.6%，其 减肥药CagriSema试验效果不及礼来的竞品，礼来涨4.8%。达美乐披萨涨6.0%，Q4营收超预期。 来源：滚动播报 ...